This review identifies challenges in genetic testing for breast cancer in low-middle-income countries, suggesting education and digital health may improve outcomes.
Globally, breast cancer is the most frequently occurring cancer among women, and prevalence has been increasing in low-middle-income countries (LMICs), including African countries. Although incidence is lower than in high-income countries (HICs), mortality remains disproportionately high due to delayed diagnosis, limited screening, and poor healthcare structures. Genetic predisposition, particularly BRCA1/2 mutations, plays a major role in hereditary breast cancer; however, access to genetic testing and counselling services is limited and unequal in many LMICs. This review synthesizes current evidence on the early detection of BRCA1/2 mutations in LMICs, with a special focus on African populations, highlighting unique challenges such as financial constraints, low awareness, and gaps in health system integration. Importantly, this study proposes a resource-adapted framework that combines targeted testing in high-risk groups, affordable genotyping approaches, digital health solutions, and community-based strategies to expand testing capacity. Implementing cost-effective, scalable approaches alongside policy support and education can expand BRCA testing capacity, ultimately improving prevention, survival, and quality of life.
No takes yet. Share an insight, caveat, or question.
Duma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: